X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the licensing agreement, the company will focus on advancing XVIR-110, which is currently being evaluated in early-stage clinical trials for the treatment of HIV infections.
Lead Product(s): XVIR-110
Therapeutic Area: Infections and Infectious Diseases Product Name: XVIR-110
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: ViiV Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 22, 2024
Details:
The proceeds will be used to advance XVIR-110, an ultra-long-acting HIV integrase inhibitor with a preclinical profile that suggests best-in-class potential for HIV pre-exposure prophylaxis, and for HIV treatment as the cornerstone of a next-generation multi-drug regimen.
Lead Product(s): XVIR-110
Therapeutic Area: Infections and Infectious Diseases Product Name: XVIR-110
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 22, 2023
Details:
XVIR-120, a novel nano-formulated prodrug of dolutegravir, across preliminary rodent and non-human primate studies which demonstrate that injections were well tolerated and support ultra-long-acting dosing intervals.
Lead Product(s): Dolutegravir Prodrug
Therapeutic Area: Infections and Infectious Diseases Product Name: XVIR-120
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
INSTI - ULA, a once yearly ultra-long-acting (ULA) injectable agent targeting HIV integrase small molecules, currently in IND-enabling studies.
Lead Product(s): INSTI - ULA
Therapeutic Area: Infections and Infectious Diseases Product Name: INSTI - ULA
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
